Shikha Baghel Chauhan

Shikha Baghel Chauhan

Auto-generated profile, based on publicly available information

Shikha Baghel Chauhan

Amity Institute of Pharmacy, Amity University, Noida, Uttar Pradesh, 201313, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Nanoscience & Nanotechnology-Asia
Verified
Journal Article
Closed access
PDF file
ASAritra Saha
Aritra Saha
SCShikha Baghel Chauhan
Shikha Baghel Chauhan
ISIndu Singh
Indu Singh
The capability of lipid-based nanoparticles (LBNs) to revolutionise cancer therapy is examined in this article. The potential of lipid-based nanoparticles (LBNs) to revolutionise cancer therapy is examined in this article. Before moving on to the formulation, characterization, and therapeutic applications of LBN, a brief discussion of the importance of targeted drug delivery is given. Liposomal delivery systems (LBNs), incorporating solid lipid nanoparticles (SLNs), liposomes and nanostructured lipid carriers, offer a versatile platform for accurate drug delivery (NLCs). The article discusses the potential of liquid nanoparticles (LBNs) in cancer therapy, highlighting their stability, storage, and techniques like reverse phase evaporation, thin-film hydration, and microemulsions. It also explores their physical characteristics, drug release studies, and role in tailored treatments. The review highlights manufacturing challenges and regulatory concerns while highlighting the evolving field of LBN applications.

27 August 2025 in Medicine in Microecology
Verified
Journal Article
Open access
NANaziya Akhtar
Naziya Akhtar
CJChirag Jain
Chirag Jain
SCShikha Baghel Chauhan
Shikha Baghel Chauhan
ISIndu Singh
Indu Singh

10 October 2025 in Drug Delivery Letters
Verified
Journal Article
Closed access
PDF file
AKAnkit Kolay
Ankit Kolay
SNSimran Nayan
Simran Nayan
SCShikha Baghel Chauhan
Shikha Baghel Chauhan
ISIndu Singh
Indu Singh
CJChirag Jain
Chirag Jain
The pharmaceutical business is transitioning to a more sustainable model, with a great-er emphasis on next-generation and green excipients to improve medicine formulation while re-ducing environmental impact. However, incorporating these innovative excipients into pharma-ceutical development presents regulatory uncertainty, safety concerns, and compliance issues. This analysis delves into the growing regulatory framework governing next-generation excipients, emphasizing the difficulties of toxicological examination, approval routes, and worldwide regula-tory agency harmonization initiatives. The article discusses the scientific advances that are driv-ing the development of green excipients, including biodegradable polymers, plant-derived stabi-lizers, and biocompatible nanocarriers, as well as their safety profiles, biopharmaceutical perfor-mance, and scalability. It also examines regulatory challenges such as the lack of standardized evaluation frameworks, the necessity for in vitro and in silico risk assessment models, and the importance of Good Manufacturing Practices (GMP) and regulatory filings in assuring compli-ance. Furthermore, this study assesses the balance between innovation and regulation, arguing that the desire for environmentally friendly pharmaceutical excipients must be balanced with se-vere safety and effectiveness criteria. The possibility for regulatory change, collaborative industry efforts, and AI-driven predictive toxicity is also investigated as a significant facilitator for speed-ing up next-generation excipient approval. As the pharmaceutical industry adopts green chemistry concepts, bridging the gap between innovation and regulatory compliance will be critical for long-term medication development. This paper discusses how to overcome present hurdles and establish a proactive regulatory environment that promotes the safe and efficient use of next-generation excipients.

1 June 2025 in Current Computer Science
Verified
Journal Article
Closed access
PDF file
DJDhruv Pratap Singh Jaitawat
Dhruv Pratap Singh Jaitawat
ISIndu Singh
Indu Singh
SCShikha Baghel Chauhan
Shikha Baghel Chauhan
The application of machine learning (ML) algorithms is causing a revolutionary change in the pharmaceutical production sector, providing previously unheard-of chances to improve productivity, precision, and creativity. From supply chain management and predictive maintenance to process optimization and quality assurance, machine learning approaches are transforming many aspects of drug manufacturing. These algorithms greatly lower production costs and minimize errors by utilizing large datasets to provide real-time analysis, anomaly detection, and predictive insights. The potential of these technologies to simplify intricate industrial processes is further enhanced by emerging trends like automation, sophisticated process control systems, and the integration of machine learning with digital twins. With an emphasis on important applications such as formulation optimization, adaptive process controls, and predictive modeling for regulatory compliance, this paper examines the changing field of machine learning in pharmaceutical production. It emphasizes how ML and Industry 4.0 technologies-like robotics and the Internet of Things (IoT)-work together to create smart industrial environments. The essay also discusses issues like algorithm openness, data privacy, and the requirement for a trained staff in order to fully utilize machine learning in this field. A key tool in addressing the rising demand for complicated biologics and tailored medications, machine learning (ML), is emerging as the pharmaceutical industry shifts to more flexible, economical, and sustainable production models. This review highlights the revolutionary impact of machine learning (ML)-driven production and offers a roadmap for its successful adoption in the pharmaceutical industry by analyzing its present status and potential future developments.

2 July 2025 in Current Pharmacogenomics and Personalized Medicine
Verified
Journal Article
Closed access
PDF file
SCShikha Baghel Chauhan
Shikha Baghel Chauhan
ISIndu Singh
Indu Singh
ADAnanya Dwivedi
Ananya Dwivedi
ADAsmitaa Dimri
Asmitaa Dimri
The introduction of artificial intelligence (AI) into dermatology has transformed customized skincare by using data-driven insights to improve treatment efficacy and accuracy. This study investigates the effects of artificial intelligenceenhanced skincare on skin microbiome diversity and pharmacogenomic accuracy, with a focus on its transformational potential in dermatological applications. The skin microbiome, an important regulator of skin health, varies greatly across people and impacts disorders including acne, eczema, and rosacea. AI-powered study of microbiome composition enables the development of customized skincare solutions that restore microbial equilibrium, improving treatment outcomes. Furthermore, pharmacogenomics— the study of genetic differences impacting medicine and skincare component responses— enables highly personalised skincare treatments that reduce side effects while increasing therapeutic benefits. AI-powered tools, such as machine learning algorithms and deep learning models, provide real-time skin evaluations, allowing for ongoing improvement of skincare regimens based on dynamic biological and environmental elements. Furthermore, AI accelerates the creation of smart biomaterials that optimise component penetration and bioavailability, hence increasing precision dermatology. Personalized skincare solutions may be tailored to an individual's unique skin profile by combining genetic insights, microbiome research, and AI-powered predictive modeling, resulting in higher treatment success. While AI-enhanced dermatology has enormous promise, issues like as data privacy, algorithm bias, and legal barriers must be addressed in order to assure ethical and successful deployment. This paper emphasizes the potential of AI in dermatology, proposing a collaborative strategy combining AI, microbiome research, and pharmacogenomics to transform customized skincare.

9 January 2019 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
SCShikha Baghel Chauhan
Shikha Baghel Chauhan
TNTanveer Naved
Tanveer Naved
NPNayyar Parvez
Nayyar Parvez
Objective: The aims of the present study were to develop different matrix patches with various ratios of hydrophilic and hydrophobic polymer combinations such as ethyl cellulose (EC) and polyvinylpyrrolidone (PVP) and eudragit RL 100 (ERL) and eudragit RS 100 (ERS) containing ethinylestradiol and medroxyprogesterone acetate and to perform physicochemical characterization and in vitro permeation studies through rat skin. Methods: Six formulations (F1 to F6) were developed by varying the concentration of both hydrophilic and hydrophobic polymer and keeping the drug load constant. Physical parameters and drug excipient interaction studies were evaluated in all the formulations. In vitro, skin permeation profiles of ethinylestradiol and medroxyprogesterone acetate from various formulations were simultaneously characterized in a thermostatically controlled modified Franz Diffusion cell. The physicochemical compatibility of the drug and the polymers was studied by differential scanning calorimetry. Results: The results suggested no physicochemical incompatibility between the drug and the polymers. In vitro permeation studies were performed by using Franz diffusion cells, patches coded as F3 (ethyl cellulose: polyvinylpyrrolidone, 7.5:2.5) and F6 (eudragit RL 100 (ERL) and eudragit RS 100 (ERS), 8:2) can be chosen for further in vivo studies. The results followed Higuchi kinetics (r = 0.9953-0.9979), and the mechanism of release was diffusion mediated. Based on physicochemical and in vitro skin permeation studies of 85.64% (for F3) and 88.62% (for F6) of ethinylestradiol and medroxyprogesterone acetate. Conclusion: The developed transdermal patches are stable, non-irritating and had increased efficacy of ethinylestradiol and medroxyprogesterone acetate and therefore had a good potential for antifertility treatment.